PMV Pharmaceuticals (NASDAQ:PMVP) Releases Earnings Results, Misses Expectations By $0.18 EPS

PMV Pharmaceuticals (NASDAQ:PMVP) released its earnings results on Tuesday. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.18), FiscalAI reports.

PMV Pharmaceuticals Stock Performance

Shares of PMVP stock remained flat at $1.26 on Thursday. 139,408 shares of the stock were exchanged, compared to its average volume of 520,734. The stock has a market capitalization of $67.36 million, a P/E ratio of -0.81 and a beta of 1.52. PMV Pharmaceuticals has a one year low of $1.02 and a one year high of $1.91. The firm has a 50 day simple moving average of $1.39 and a 200-day simple moving average of $1.31.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. Wall Street Zen downgraded shares of PMV Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Sunday. Weiss Ratings upgraded shares of PMV Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, September 24th. Finally, HC Wainwright restated a “buy” rating and set a $5.00 target price on shares of PMV Pharmaceuticals in a research note on Friday, September 4th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $4.33.

PMV Pharmaceuticals Company Profile

PMV Pharmaceuticals, Inc. is a clinical-stage precision oncology company focused on developing therapies that target cancer-causing mutations in the tumor suppressor protein p53. The company aims to discover and develop small-molecule medicines designed to restore the normal tumor-suppressing function of mutant p53 proteins. PMV’s lead product candidate is rezatapopt, also known as PC14586, an investigational oral therapy designed to selectively target the p53 Y220C mutation. This mutation occurs in a range of solid tumors, and rezatapopt is being evaluated for its potential to reactivate the altered p53 protein and inhibit cancer-cell growth.